Meanwhile, the Ministry of Foreign Affairs, when asked about the development, said, “The vaccination process is just beginning in India, to provide an early specific response on supplies to other countries. We will make a decision in this regard in due course and it may take some time.”
“To enable the immediate implementation of our national immunization program,” the Brazilian president wrote to Prime Minister Narendra Modi requesting “two million doses of the immunization device produced by the India Serum Institute.”
The letter states that “the Brazilian government has launched a national immunization program against Covid-19” and “among the vaccines selected by the Brazilian government, those from the Indian company Bharat Biotech Internacional Limited (Covaxin) and AstraZeneca at the University of Oxford (Coffeeshield), produced by the Institute India serum. “
It is important to note that Brazil will produce 100 million doses of AstraZeneca vaccine by the National Institute of Health / Fiocruz Laboratory. Fiocruz is now getting ready-made vaccines from India’s Serum Institute, one of the vaccine production centers.
Earlier in January 2021, Bharat Biotech signed an agreement with Brazilian company Precisa Medicamentos for the Covaxin COVID-19 vaccine. A team from Precisa Medicamentos visited the Bharat biotech facility in Hyderabad.
“In principle, it is understood between the parties that the supply of Covaxin will have priority in the public market, through direct purchase by the government. Brazil,” the company said in a statement. Supplies to the private market will be based on receipt of a market license from ANVISA, the Brazilian regulatory authority.
India is known as the pharmaceutical capital of the world, a position it has reaffirmed during the Covid pandemic by sending HCQ and paracetamol to about 150 countries around the world. The Indian prime minister said India’s vaccine would be for humanity, with priority given to the developing world and the neighborhood.